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Luliconazole mostly prescribed drug for the management of superficial problems, the very simple, Fast, accurate 
and economical methods have been proposed for the determination of Luliconazole cream. Luliconazole  was 
measured by using Uv spectroscopy method with the solution of mrthanol and purified water the linearity was 
found to be 0.9987 and the accuracy showed mean % RSD of 0.921776 and with total meam % RSD 1.10130 in 
intermediate precision, robustness %RSD 0.543539 all the paranmeters values were within standard limit thus 
Analytical method was validated according to ICH guideline for the determination of Luliconazole cream. The 
method was found to be precise and validated as per ICH guidelines. 
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The superficial mycoses are global problems, which affect 20 to 25% of the world’s population, leading to 
degradation of quality of life in terms of cosmetic deformity. Luliconazole is a broad-spectrum antifungal agent 
with imidazole group mostly prescribed for the treatment of dermatological problems like superficial mycoses. 
[1] the chemical name of Luliconazole is (2E)-2-[(4R)-4-(2, 4-dichlorophenyl)-1, 3-dithiolan-2-ylidene]-2-
imidazol-1-ylacetonitrile with molecular formula C14H9Cl2N3S2, and molecular weight 354.28.  Luliconazole is 
yellowish powder. The USFDA approved that the 1 % of Luliconazole cream is indicated for the topical 
treatment of interdigital tineapedis, tineacruris, and tineacorporis [2] The characteristic of drug is  poorly water-
soluble as well as high permeability. It is low toxic well tolerable, being both fungistatic and fungicidal with 
minimum inhibitor concentration, MIC 0.004– 0.008μg/ml for most of the dermatophytes [1, 5]. The mechanism 
of action of LNZ is inhibition of Cytochrome P450 2C19 [6].Luliconazole  inhibit the enzyme Lanosterol 
demethylase which is required for the synthesis of Ergosterol, a major component of the fungus cell membranes 
[7]. In Indian Pharmacopoeia (IP), British Pharmacopoeia (BP) and United States Pharmacopoeia (USP), 
Luliconazole is not official drug. A Review of literature reported very few methods such as LC-MS/MS [8] 
method (toe nails) HPLC for related substances [9], HPTLC method for assay in formulation and biofluid [10], 
and a single UV spectroscopic method [11] (area under curve) for assay of Luliconazole. There is not a simple 
method reported for the detection of the drug in pharmaceutical formulation by UV spectrophotometry. So, this 
research tends to establish a simple, fast, accurate, precise, reproducible and economic method for assay of 
Luliconazole dosage forms, which can be used in quality control laboratories. This paper reports a study on the 
development of new validated UV- spectrophotometric methods for the quantitative determination of 
Luliconazole in creams. The developed methods were validated as per ICH guidelines 
2. Materials and methods 
Reference Luliconazole was obtained as gift sample from Time Pharmaceuticals (Mukundapur-5, vhaisakhori). 
Methanol (AR) grade was supplied by Thermo Fisher Scientific India Private Limited and Luliconazole cream 
form (cream, ) containing 1% w/w of Luliconazole was procured from local pharmacy. Sodium acetate was 
procured from Thermo Fisher Scientific India Private Limited. Throughout the analytical process distilled water 
was used. 
2.1 Instrumentation 
A PerkinElmer UV-Visible spectrophotometer (λ 365) with an even set of 10 mm quartz cuvettes were used for 
measurement of absorbance for the analysis. All analytical weight measurements were done on a PRECISA 
(XB120A) electronic balance. 
2.2 Preparation of Calibration curve 
Standard stock solution was prepared by transferring 10mg of Luliconazole into 10ml volumetric flask and it 
was dissolved with methanol. Working standard solution was prepared by taking 2.5ml of stock solution into a 
25ml volumetric flask. The volume was made up to mark to produce 100µg/ml solution with methanol and 




distilled water. From the above working solution 0.2ml, 0.5ml, 1ml, 1.5ml, 2ml and 2.5ml were pipetted and 
transferred to 6 individual 10 ml volumetric flask and finally the volume was made upto the mark with diluent. 
Solutions were scanned from 200-400 nm UV range by using UV-Visible double beam spectrophotometer. 
Assay 
2.3 Preparation of Standard Solution 
Dissolve 50 mg of Luliconazole WS in 30 ml of methanol, sonicate it to dissolve and add sufficient methanol to 
produce 50ml. Dilute 1 ml of the solution to 100 ml with methanol.  
2.4 Sample preparation    
Weigh accurately about 1 gm of the cream and dissolve in 70 ml methanol, sonicate for 10 minute and add 
sufficient methanol to produce 100 ml. filter the resulting solution with whatmann filter paper. Further dilute the 
5 ml of filtrate solution to 50 ml with methanl.  
2.5 Procedure 
Measure the absorbance of both the standard and sample solution in a UV visible spectrophotometer having 1 
cm pathlength at a wavelength of 296 nm against blank and calculate the content of Luliconazole using 
following formula. 
2.6 Calculation 
(Content of Luliconazole  in % w/w) 
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Where,  
Wsp = Weight of sample  Wstd = Weight of standard                      
LOD = Loss on drying 
3. Method validation 
3.1 System suitability 
For the system suitability testing five replicate of standard solution was prepared and sample s were also 
analyzed and % RSD was calculated.  
 




Table 1: System suitability Luliconazole WS Specificity 
Sr. No Test solution Peak Abs. 
1 Std1 0.5289 
2 Std2 0.5283 
3 Std3 0.5292 
4 Std4 0.5288 
5 Std5 0.5282 
 Average: 0.52868 
 %RSD: 0.07957813 
3.2 Placebo preparation 
The excipients used in the formulation of Luliconazole in similar unit (aroung 5 gm ) ws prepared where, about 
1 g was weighted and dissolved in around 70 ml of methanol. The solution was sonicated for 5 min and volume 
was made up to 100 ml with the same solvent. The solution was filtered through whatmann no 4. Standard and 
sample solution was prepared as similar method and the absorbance was compared between placebo, standard 
and the sample solution to see the interference of the placebo in the sample. 
Result: there was slightly interference of the placebo observed in the sample 
3.3 Accuracy  
Placebo solution was prepared. 100 % standard solution was prepared in triplicates. 
Three different concentrations (50%, 100% and 150% ) of sample solution were prepared by adding known 
amount of drug substance to placebo. All the sample solutions were prepared in triplicates. All the samples were 
analyzed and the % recovery was calculated along with the % RSD. 
Table 2: Percentage recovery data of Luliconazole 
Percentage Amount taken (std) in g Amount taken in gm % Recovered Mean recovery (%) % RSD 
50 0.0256 0.5233 99.86 99.29 0.695565 
  0.5250 98.52   
  0.5114 99.48   
100  1.025 98.32 98.97 0.893785 
  1.0115 98.62   
  1.0473 99.98   
150  1.5091 100.29 100.07 1.071868 
 





a) System Precision (Repeatability) 
a. Six replicate of standard solutions was prepared 
b. According to the procedure samples were analyzed 
c. % RSD was calculated for the peak of the standard solutions 
Table 3: System Precision 
Sr. No. Test solution Peak Abs. 
1 Standard 1 0.5265 
2 Standard 2 0.5252 
3 Standard 3 0.5249 
4 Standard 4 0.5251 
5 Standard 5 0.5251 
6 Standard 6 0.5255 
 Average: 0.52538 
 % RSD: 0.110603 
b) Intermediate precision ( Ruggedness) 
a. Six replicate of standard and six individual sample solutions by three analysts was prepared on the first 
day keeping the other condition same. 
b. According to the procedure samples were analyzed. 
c. Second day again six replicate of the samples by three analysts was prepared keeping the other conditions 
same. 
d. According to the procedure samples were analyzed. 
e. The individual day and combined day area between three analyst was compared and showed in the table 
below. 
Analyst: A                    Analyst: B                              Analyst: C 
Day: 1                           Day: 1                                     Day: 1 
Day: 2                           Day: 2                                     Day: 2 
 





Analyst A: Day 1 
Sr. No. Test Solution Weight (g) Peak Abs. Assay (%) 
1 Standard 0.0256 0.5288  
2 Sample 1 0.5233 0.2721 99.86 
3 Sample 2 0.5250 0.2693 98.52 
4 Sample 3 0.5114 0.2649 99.48 
5 Sample 4 1.025 0.5247 98.32 
6 Sample 5 1.0115 0.5194 98.62 
7 Sample 6 1.0473 0.5452 99.98 
Average % 99.13    
RSD %: 0.736642    
Analyst B: Day 1 
Sr. No. Test Solution Weight (g) Peak Abs. Assay (%) 
1 Standard 0.0256 0.52538  
2 Sample 1 0.5278 0.2736 100.21 
3 Sample 2 0.5201 0.2714 100.87 
4 Sample 3 0.5253 0.2769 101.90 
5 Sample 4 1.011 0.5251 100.40 
6 Sample 5 1.009 0.5155 98.76 
7 Sample 6 1.0063 0.5106 98.09 
Average % 100.04    
RSD %: 1.395737    
Analyst C: Day 1 
Sr. No. Test Solution Weight (g) Peak Abs. Assay (%) 
1 Standard 0.0257 0.5278  
2 Sample 1 1.024 0.5222 98.51 
3 Sample 2 1.005 0.5176 99.49 
4 Sample 3 1.039 0.5396 100.32 
5 Sample 4 1.522 0.776 98.49 
6 Sample 5 1.5006 0.7791 100.29 
7 Sample 6 1.5012 0.783 100.76 
Average % 99.64    
RSD %: 0.979314    




Analyst A: Day 2 
Sr. No. Test Solution Weight (g) Peak Abs. Assay (%) 
1 Standard 0.0256 0.5264  
2 Sample 1 1.025 0.5256 98.93 
3 Sample 2 1.0115 0.525 100.14 
4 Sample 3 1.0058 0.5277 101.22 
5 Sample 4 1.0099 0.5284 100.95 
6 Sample 5 1.0130 0.5229 99.29 
7 Sample 6 1.0473 0.5322 98.04 
Average % 99.76    
RSD %: 1.232595    
Analyst B: Day 2 
Sr. No. Test Solution Weight (g) Peak Abs. Assay (%) 
1 Standard 0.0256 0.529  
2 Sample 1 0.5278 0.2766 100.61 
3 Sample 2 0. 5201 0.2678 98.85 
4 Sample 3 0.5253 0.2683 98.06 
5 Sample 4 1.011 0.5189 98.54 
6 Sample 5 1.009 0.5179 98.54 
7 Sample 6 1.0063 0.5201 99.23 
Average % 99.76    
RSD %: 1.232595    
Analyst C: Day 2 
Sr. No. Test Solution Weight (g) Peak Abs. Assay (%) 
1 Standard 0.0257 0.528  
2 Sample 1 1.024 0.5248 98.96 
3 Sample 2 1.005 0.5296 101.76 
4 Sample 3 1.039 0.5296 98.56 
5 Sample 4 1.522 0.7804 99.01 
6 Sample 5 1.5006 0.7855 101.08 
7 Sample 6 1.5012 0.7849 100.96 
Average % 100.06    
RSD %: 1.36327    
 




Table 4: RSD between three analyst on two different days 
Analysts Day 1 Day 2 
A (%RSD) 0.736642 1.232595 
B (%RSD) 1.39737 0.900267 
C (%RSD) 0.979314 1.36327 
Mean % RSD 1.03723 1.16537 
Total Mean % RSD 1.1013  
3.5 Linearity 
a) The sample solution of 80%, 90%, 100 % and 120 % concentration of sample weight were prepared. 
b) According to the procedure the samples were analyzed. 
c) The calibration curve where, concentration versus peak area of solution was plotted. 
d) The correlation coefficient, slope, y-intercept from the calibration curve was determined. 
Table 5: obtained Peak abs. at 296 nm 
Sr. No. Concentration of Analyte Peak Abs. at 296 nm 
1 80% 0.4303 
2 90% 0.4957 
3 100% 0.5548 
4 110% 0.612 
5 120% 0.6831 









0.6831 y = 0.0062x - 0.0667 




















Linearity curve of Luliconazole 





a) Three sample solutions were prepared according to the analytical method with minor deviations. The 
minor deviations was changed in wavelength ±1 nm. 
b) The samples were analyzed according to the procedure and assay % was calculated. 
Table 6:  Change in wavelength: Abs, at 297 nm 
Sr. No. Test solution Weight (g) Abs. Assay ( %) 
1 Standard 0.0256 0.5296  
2 Sample 1 1.0058 0.5233 99.77 
3 Sample 2 1.0099 0.5202 98.78 
4 Sample 3 1.0130 0.5264 99.65 
Average % 99.40    
% RSD 0.543539    
Table 7: Change in wavelength: Abs at 295 nm 
Sr. No. Test solution Weight (g) Abs. Assay ( %) 
1 Standard 0.0256 0.5345  
2 Sample 1 1.025 0.5271 99.06 
3 Sample 2 1.0115 0.524 98.68 
4 Sample 3 1.0473 0.5295 99.98 
Average % 99.24    
% RSD 0.67355    
3.7 Range  
Table 8 
Sr. No. Concentration of 
Analyte 
Peak Abs. at 296 nm % Recovery 
1 80% 0.4303 101.78 
2 90% 0.4957 101.87 
3 100% 0.5548 100.18 
4 110% 0.612 99.05 
5 120% 0.6831 100.78 
 Mean % Recovery 100.73  





4. Result and Discussion 
A simple and reliable method has been developed for the determination of assay of Luliconazole in semisolid 
dosage formulation. Beers law was followed in concentration range of 80 %-150 % for Luliconazole at 296 nm 
in methanol and  water. Correlation coefficient (R
2
) was found to be 0.9987. The precision was studied for 




System Precision, i.e., Repeatability (% RSD less than 2 %, i.e., 0.9987) and Intermediate precision, i.e., 
Ruggedness with three analyst for two different days keeping other conditions same and it is concluded that % 
RSD, Mean % RSD, Total Mean % RSD was found in the range of 0.7366-1.3957, 1.03723-1.16537, 1.1013 
respectively which indicates that method is reliable and very likely to produce the same and predictive results. 
Accuracy of the method was determined by calculating the mean % recovery at 50 %, 100 % and 150 % level 
and found in the range of 98.97 to 100.07 %. Range was determined by calculating Mean % Recovery (i.e., 
100.73) and Correlation Coefficent (i.e., R
2
= 0.9987) at 80-120 % concentration of Luliconazole which indicates 
that set method is precise, accurate and linear at 80-120 % concentration level. Robustness was studied by 
slightly changing the wavelength i.e. ± 1nm and results indicate that the method remains unaffected by small 
variation in wavelength.  
5. Conclusion 
The observation and results obtained from the validation study clearly indicated that the developed analytical 
method is accurate, precise, specific and linear. Since all the result are within the limit, the above stated 
analytical method is validated as per the ICH guidelines and can be employed for routine analysis of 
Luliconazole in semisolid dosage form. In regard to constraint/limitations of the study, slight interference of the 
placebo in the sample was observed which affects the specificity of the method.  Study was conducted using 
methanol only as solvent, however, Luliconazole is soluble in other organic solvents as well such as  ethanol, 
dimethyl formide.  
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